High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.
1 previously untreated patient with plasma-cell leukaemia and 8 patients with myeloma (4 previously untreated) were treated with high-dose melphalan 100-140 mg/m2 iv. All responded to treatment. 3 of the 5 previously untreated patients achieved biochemical and bone-marrow complete remissions.
D000328:Adult; D000367:Age Factors; D001536:Bence Jones Protein / Q000652:urine; D016026:Bone Marrow Transplantation; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007952:Leukemia, Plasma Cell / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008558:Melphalan / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000628:therapy; D009503:Neutropenia / Q000139:chemically induced; D059408:Pain Management; D014182:Transplantation, Autologous
D001536:Bence Jones Protein; D008558:Melphalan